{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Capsule+2&page=100",
    "query": {
      "intervention": "Capsule 2",
      "page": 100
    },
    "page_size": 10
  },
  "pagination": {
    "page": 100,
    "page_size": 10,
    "total_count": 5062,
    "total_pages": 507,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Capsule+2&page=101&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Capsule+2&page=99&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T10:06:02.348Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03029429",
      "title": "Theophylline Treatment for Pseudohypoparathyroidism",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pseudohypoparathyroidism",
        "Albright Hereditary Osteodystrophy"
      ],
      "interventions": [
        {
          "name": "Theophylline",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "13 Years to 99 Years"
      },
      "enrollment_count": 29,
      "start_date": "2018-09-01",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-11-17T10:06:02.348Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03029429"
    },
    {
      "nct_id": "NCT00685737",
      "title": "Safety of a Hypolipidemic Agent in Healthy Normal Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "1-MNA",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharmena North America",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 20,
      "start_date": "2007-12",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2008-06-27",
      "last_synced_at": "2026-11-17T10:06:02.348Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00685737"
    },
    {
      "nct_id": "NCT01652729",
      "title": "Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Type 2"
      ],
      "interventions": [
        {
          "name": "Exenatide once weekly suspension",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 365,
      "start_date": "2013-02",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2015-08-20",
      "last_synced_at": "2026-11-17T10:06:02.348Z",
      "location_count": 60,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01652729"
    },
    {
      "nct_id": "NCT00040664",
      "title": "A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "ritonavir",
          "type": "DRUG"
        },
        {
          "name": "fosamprenavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 69,
      "start_date": "2002-07",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2017-03-03",
      "last_synced_at": "2026-11-17T10:06:02.348Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00040664"
    },
    {
      "nct_id": "NCT03597464",
      "title": "Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lupus Nephritis"
      ],
      "interventions": [
        {
          "name": "Voclosporin",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aurinia Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 216,
      "start_date": "2019-09-29",
      "completion_date": "2021-10-07",
      "has_results": true,
      "last_update_posted_date": "2022-12-14",
      "last_synced_at": "2026-11-17T10:06:02.348Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03597464"
    },
    {
      "nct_id": "NCT00322465",
      "title": "NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urethritis"
      ],
      "interventions": [
        {
          "name": "Doxycycline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Tinidazole",
          "type": "DRUG"
        },
        {
          "name": "Azithromycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "16 Years to 45 Years · Male only"
      },
      "enrollment_count": 305,
      "start_date": "2006-11-17",
      "completion_date": "2009-04-20",
      "has_results": true,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-11-17T10:06:02.348Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • New Orleans, Louisiana • Baltimore, Maryland + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00322465"
    },
    {
      "nct_id": "NCT02629692",
      "title": "Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Healthy (For Part A)",
        "Chronic Myeloid Leukemia (for Part B and C)"
      ],
      "interventions": [
        {
          "name": "Vodobatinib (K0706) capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharma Advanced Research Company Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2016-06-27",
      "completion_date": "2025-01-03",
      "has_results": true,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-11-17T10:06:02.348Z",
      "location_count": 8,
      "location_summary": "Downey, California • Los Angeles, California • Jacksonville, Florida + 5 more",
      "locations": [
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02629692"
    },
    {
      "nct_id": "NCT01024244",
      "title": "A Study of LY2599506 in Patients With Type 2 Diabetes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "LY2599506",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 78,
      "start_date": "2009-12",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2011-12-02",
      "last_synced_at": "2026-11-17T10:06:02.348Z",
      "location_count": 3,
      "location_summary": "Topeka, Kansas • Toms River, New Jersey • Syracuse, New York",
      "locations": [
        {
          "city": "Topeka",
          "state": "Kansas"
        },
        {
          "city": "Toms River",
          "state": "New Jersey"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01024244"
    },
    {
      "nct_id": "NCT00958334",
      "title": "Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Uterine Fibroids"
      ],
      "interventions": [
        {
          "name": "Proellex®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Repros Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 65,
      "start_date": "2006-09-07",
      "completion_date": "2008-10-15",
      "has_results": true,
      "last_update_posted_date": "2019-06-18",
      "last_synced_at": "2026-11-17T10:06:02.348Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • San Diego, California • Denver, Colorado + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00958334"
    },
    {
      "nct_id": "NCT02784444",
      "title": "A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-alcoholic Fatty Liver Disease",
        "Non-alcoholic Steatohepatitis",
        "NASH - Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "MSDC-0602K",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cirius Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 392,
      "start_date": "2016-09-14",
      "completion_date": "2019-06",
      "has_results": true,
      "last_update_posted_date": "2020-09-16",
      "last_synced_at": "2026-11-17T10:06:02.348Z",
      "location_count": 43,
      "location_summary": "Chandler, Arizona • Tucson, Arizona • Chula Vista, California + 37 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02784444"
    }
  ]
}